SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.

A recent study reaffirmed the safety and effectiveness of guselkumab, in managing psoriasis and psoriatic arthritis over an extended period of 208 weeks (approximately 4 years). This ...

In winters, the problem of scalp itching increases due to dandruff. If there is a severe itching and burning sensation on the scalp, then it can also be an infection. Know the remedies to get rid of ...

The team, led by Hye Sun Gwak, analyzed data from 13 studies and found that several types of blood pressure medications—ACE ...

Women with psoriasis had increased risks for preeclampsia/eclampsia and cardiac arrhythmias during delivery hospitalizations, according to a real-world study evaluating maternal cardiovascular ...

Lucknow: King George's Medical University (KGMU) will soon offer advanced treatment options for conditions such as vitiligo (leukoderma) and psoriasis.

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies ...

The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...

Living with chronic, persistent pain is a fact of life for 3 out of 10 people in the U.S. What people would give up to reduce ...